Results of Precision Biologics Phase 2 Colorectal Cancer Study Published in Clinical Cancer Research
Precision Biologics announces that the results of the Phase II Clinical Trial using its lead...
30Apr
01Mar
Precision Biologics to Deliver two Oral Presentations on our Clinical and Scientific Programs at the World Immunotherapy Conference, March 2-4, 2020, San Diego, CA
Dr Massimo Fantini, Senior Scientist is Presenting the following Talk entitled: "Mechanisms of action of...
25Feb
In Memoriam: Dr. Ariel Hollinshead
Ariel Cahill Hollinshead Hyun, PhD, a pioneering cancer researcher whose work contributed to the foundation...
07Feb
Indirect mechanisms of action of a novel IgG1 monoclonal antibody, NEO-201, that enhance immune killing of tumor
NEO-201 is an IgG1 mAb targeting variants of CEACAM5/6 that demonstrates tumor sensitivity and specificity....
23Jan
Phase 1 with Expansion Cohorts in a Study of NEO-201 in Adults with Chemo-Resistant Solid tumors
This is a first-in-human phase 1 study to determine the maximum tolerated dose (MTD) and...
16Jan
The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity
The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of...
17Dec
Rationale, discovery and clinical development of NEO-201
Most monoclonal antibody cancer therapies are developed for known targets and are commercially approved for...
06Nov
SITC 2019
An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T...
27Oct
Immuno-Oncology Europe 2019
Discovery and Development of Monoclonal Antibodies Targeting Tumor Neo-Epitopes Presented by Dr. Philip Arlen President and CEO,...
15Oct
Novel Targets Of Neoantigens In Monoclonal Antibodies
Philip M. Arlen, M.D. Summary: Target is broadly expressed in multiple solid tumors. Exhibits both ADCC and CDC...